Korro Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing operational updates including its ongoing ANCHOR clinical trial and the pending termination of its Novo Nordisk collaboration.
Key Highlights
- Shares outstanding: As of November 3, 2026, the company had 13,725,646 shares of common stock, $0.001 par value per share, outstanding.
- ANCHOR trial: According to the filing, the company's Phase 1/2 clinical trial of KRRO-121, designated ANCHOR, includes completion of Part 1 in healthy volunteers and planned dosing of patients with urea cycle disorders, or UCD.
- KRRO-111 program: The filing identifies KRRO-111 as being in preclinical development, with ongoing studies and timing of regulatory submission noted as a forward-looking item.
- Novo Nordisk termination: The filing discloses the termination of the company's collaboration and license agreement with Novo Nordisk A/S, with remaining deferred revenue under the agreement expected to be recognized in the fourth quarter of 2026.
- Regulatory designations: The filing references orphan drug designation granted by the European Commission and rare pediatric disease designation granted by the FDA for KRRO-121 for the treatment of UCD.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not classified as an emerging growth company.
Korro Bio's Third-Quarter 2026 Filing: Pipeline Status and Collaboration Update
Korro Bio, Inc. (NASDAQ:KRRO), a Cambridge, Massachusetts-based biotechnology company focused on RNA-editing oligonucleotides, or REOs, filed its quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2026. The report was filed on November 5, 2026, and covers the company's operations as a Delaware corporation. As of November 3, 2026, the registrant reported 13,725,646 shares of common stock outstanding at a par value of $0.001 per share.
According to the filing, the company's lead development candidate, KRRO-121, is being evaluated in the ANCHOR Phase 1/2 clinical trial program. The filing describes forward-looking items including the completion of Part 1 of ANCHOR in healthy volunteers, the planned initiation of dosing in patients with urea cycle disorders, and the timing of an interim clinical readout. The filing also notes that KRRO-121 has received orphan drug designation from the European Commission and rare pediatric disease designation from the FDA for the treatment of UCD, and discusses the potential development and regulatory pathway for KRRO-121 in hepatic encephalopathy, or HE.
A second program, KRRO-111, is described in the filing as being in preclinical development, with the company disclosing ongoing studies and referencing the timing of a regulatory submission as a forward-looking matter. Separately, the filing discloses the termination of the company's collaboration and license agreement with Novo Nordisk A/S, stating that the company expects to recognize the remaining deferred revenue under that agreement in the fourth quarter of 2026. Wind-down cost reimbursement is also referenced as an element of the termination. The company disclosed that it is a non-accelerated filer and smaller reporting company for purposes of Exchange Act classifications. The filing's forward-looking statements are expressly subject to the company's cautionary language regarding known and unknown risks and uncertainties.
What Was Disclosed
Korro Bio filed its Form 10-Q for the quarter ended September 30, 2026, reporting 13,725,646 shares outstanding, disclosing the status of its ANCHOR and KRRO-111 programs, and noting the termination of its Novo Nordisk collaboration with deferred revenue recognition expected in Q4 2026.



Please wait processing your request...